NA
QNCX icon

Nordwand Advisors’s Quince Therapeutics QNCX Stock Holding History

Nordwand Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.03K Buy
+100
New +$20.1K ﹤0.01% 150

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nordwand Advisors's QNCX Position: Q1 2026 in Review

Nordwand Advisors opened a new position in Quince Therapeutics (QNCX) in Q1 2026: 100 shares worth $2.03K. The stake represents ﹤0.01% of the portfolio and ranks #150 among its holdings.

43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Nordwand Advisors held 100 shares of Quince Therapeutics worth $2.03K as of Q1 2026.
  • Quince Therapeutics was a new Nordwand Advisors position in Q1 2026.
  • Quince Therapeutics made up ﹤0.01% of Nordwand Advisors's portfolio in Q1 2026, its #150 holding.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Nordwand Advisors's 13F filing for Q1 2026, filed 7 May 2026.